Many substances contribute to the formation of fibrin in blood ; some of these disappear during clotting and others can be found in high concentration in serum. The factors which disappear, or are consumed, may be considered to be substrates which are converted into active substances during clotting while those which remain in serum are more likely to be enzymes.
Many workers have studied the consumption of prothrombin during coagulation (Bordet & Delange, 1912 ; Quick, 1047 ; Soulier, 1948 ; Merskey, 1950) . From these observations it appears that in haemorrhagic states where there is defective formation of intrinsic thromboplastin (as in thrombocytopenia, haemophilia and the presence of inhibitors of the thromboplastin mechanism) prothrombin is incompletely consumed. In tromexan therapy (deficiency of factor VII), and in ' Christmas disease (deficiency of ' Christmas factor ') there is also abnormal prothrombin consumption (Biggs et al., 1952 ; Douglas, 1953) . Graham et al. (1951) report on the normal utilization of antihaemophilic factor during clotting, determining the amount of this factor remaining in serum by its effect on the prothrombin consumption of haeniophilic dog blood. They concluded that antihaemophilic globulin is rapidly consumed during and after clotting, the rate of consumption of prothrombin and antihaemophilic globulin being similar. Alexander et al. (1951) have studied factor V consumption during physiological coagulation. Factor V was assayed by its ability to correct the clotting defect of stored oxalated plasma in which factor V (being labile) is deficient. They found that factor V disappeared during physiological coagulation, the decrease beginning promptly after the blood was shed. Owen and Bollman (1948) Some of the methods used have been described in previous communications but many of the techniques are new and, since they have quite wide application in research 011 blood clotting, they will be described in detail with illustrations of their use.
The preparation of the following reagents is described by Biggs and Macfarlane (1953) Prothrombin, thrombin, fibrinogen, aluminium hydroxide Ca (alumina), human brain extract and M/40 calcium chloride.
The construction of a thrombin-fibrinogen dilution curve is described by Biggs (1951) and Biggs and Macfarlane (1953) .
The thromboplastin generation test and the reagents required for this (platelets, alumina treated plasma, and serum) are described by Biggs and Douglas (1953 (Quick et al., 1949 ; Merskev, 1950 (Biggs, 1951) . This method can be used either to compare the prothrombin content of two plasma samples or to compare the prothrombin present in serum with that in plasma. The use of the method to compare serum with plasma is described. 1 ml. of citrated plasma or citrated serum (collected as described above) is diluted with !) ml. of distilled water in a centrifuge tube. By the addition of !% acetic acid the pH is adjusted to 5.0. The resulting precipitate is collected by centrifuging and washed twice with distilled water likewise acidified, centrifuging between each washing. The final precipitate is dissolved in 2 ml. of citrate-saline and the pH readjusted to 7.0 with 0.5% Na2CO:i. Fig. 4 . This specimen contained approximately 20% of factor V.
Antihaemophilic globulin consumption. This is studied, using the thromboplastin generation test (Biggs et (Biggs & Douglas, 1953b Prothrombin.
The mean results of carrying out the prothrombf n consumption test on 20 normal subjects is shown in Fig. 5 and by experiments on the effects of glass contact (Biggs ct al., 1953b) , *t is possible to visualise the changing pattern of blood constituents during clotting (Fig. 10) 
